NASDAQ:HALO - Halozyme Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.60 +0.31 (+1.69 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$18.60
Today's Range$18.1969 - $18.62
52-Week Range$11.41 - $21.48
Volume911,811 shs
Average Volume932,218 shs
Market Capitalization$2.68 billion
P/E Ratio41.33
Dividend YieldN/A
Beta1.88

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889

Debt

Debt-to-Equity Ratio0.39
Current Ratio4.06
Quick Ratio4.03

Price-To-Earnings

Trailing P/E Ratio41.33
Forward P/E Ratio-20.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$316.61 million
Price / Sales8.46
Cash Flow$0.4553 per share
Price / Cash40.85
Book Value$1.84 per share
Price / Book10.11

Profitability

EPS (Most Recent Fiscal Year)$0.45
Net Income$62.97 million
Net Margins21.52%
Return on Equity45.31%
Return on Assets15.93%

Miscellaneous

Employees255
Outstanding Shares143,970,000

Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.03. The biopharmaceutical company had revenue of $30.90 million for the quarter, compared to analyst estimates of $31.84 million. Halozyme Therapeutics had a return on equity of 45.31% and a net margin of 21.52%. The company's revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. View Halozyme Therapeutics' Earnings History.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Halozyme Therapeutics.

What price target have analysts set for HALO?

8 Wall Street analysts have issued 12-month target prices for Halozyme Therapeutics' shares. Their predictions range from $7.00 to $29.00. On average, they expect Halozyme Therapeutics' share price to reach $19.75 in the next year. View Analyst Ratings for Halozyme Therapeutics.

Who are some of Halozyme Therapeutics' key competitors?

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 55)
  • Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 50)
  • Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)
  • Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)
  • Dr. Michael J. LaBarre Ph.D., Chief Scientific Officer and VP (Age 54)

Has Halozyme Therapeutics been receiving favorable news coverage?

Media stories about HALO stock have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a media sentiment score of 0.07 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.06%), Iridian Asset Management LLC CT (5.70%), JPMorgan Chase & Co. (2.17%), First Eagle Investment Management LLC (2.09%), Artisan Partners Limited Partnership (1.18%) and Northern Trust Corp (1.15%). View Institutional Ownership Trends for Halozyme Therapeutics.

Which major investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Iridian Asset Management LLC CT, BlackRock Inc., Rubric Capital Management LP, Russell Investments Group Ltd., American Century Companies Inc., Millennium Management LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Halozyme Therapeutics.

Which major investors are buying Halozyme Therapeutics stock?

HALO stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc., Alambic Investment Management L.P., Victory Capital Management Inc., GSA Capital Partners LLP, UBS Group AG and Federated Investors Inc. PA. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $18.60.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.68 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]


MarketBeat Community Rating for Halozyme Therapeutics (HALO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  278 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  501
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Halozyme Therapeutics (NASDAQ:HALO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Halozyme Therapeutics in the last 12 months. Their average twelve-month price target is $19.75, suggesting that the stock has a possible upside of 6.18%. The high price target for HALO is $29.00 and the low price target for HALO is $7.00. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.382.292.43
Ratings Breakdown: 2 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.75$19.75$19.00$17.5714
Price Target Upside: 6.18% upside2.65% upside3.46% downside7.92% downside

Halozyme Therapeutics (NASDAQ:HALO) Consensus Price Target History

Price Target History for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018BarclaysDowngradeEqual Weight ➝ Underweight$19.00HighView Rating Details
2/22/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$18.00 ➝ $19.00LowView Rating Details
2/21/2018Canaccord GenuityBoost Price TargetBuy$19.00 ➝ $21.00HighView Rating Details
2/21/2018JPMorgan ChaseReiterated RatingOverweight ➝ Overweight$19.00 ➝ $22.00LowView Rating Details
1/24/2018Deutsche BankSet Price TargetBuy$21.00LowView Rating Details
1/24/2018Goldman SachsInitiated CoverageNeutral ➝ Neutral$20.00HighView Rating Details
10/16/2017Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $29.00N/AView Rating Details
8/10/2017Jefferies GroupReiterated RatingUnderperform$6.75 ➝ $7.00HighView Rating Details
1/6/2017CitigroupDowngradeBuy ➝ NeutralN/AView Rating Details
9/8/2016Wells FargoReiterated RatingBuyN/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Halozyme Therapeutics (NASDAQ:HALO) Earnings History and Estimates Chart

Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.28)($0.28)($0.28)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.26)($0.26)($0.26)
Q4 20181($0.24)($0.24)($0.24)

Halozyme Therapeutics (NASDAQ HALO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.22)N/AView Earnings Details
5/10/2018Q1 2018($0.22)($0.19)$31.84 million$30.90 millionViewN/AView Earnings Details
2/20/2018Q4 2017$0.58$0.85$173.11 million$189.60 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.06$0.0190$58.95 million$63.73 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.23)$31.76 million$33.80 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.26)$30.79 million$29.60 millionViewListenView Earnings Details
2/28/2017Q416($0.30)($0.21)$37.94 million$39.00 millionViewListenView Earnings Details
11/7/2016Q316($0.27)($0.23)$34.43 million$31.90 millionViewListenView Earnings Details
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.18)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
8/5/2011Q2 2011($0.13)$0.03ViewN/AView Earnings Details
5/6/2011Q1 2011($0.13)($0.10)ViewN/AView Earnings Details
3/11/2011Q4 2010($0.12)($0.17)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.13)($0.13)ViewN/AView Earnings Details
8/6/2010Q2 2010($0.14)($0.13)ViewN/AView Earnings Details
5/7/2010Q1 2010($0.16)($0.13)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.16)($0.14)ViewN/AView Earnings Details
11/6/2009Q3 2009($0.18)($0.16)ViewN/AView Earnings Details
8/7/2009Q2 2009($0.16)($0.21)ViewN/AView Earnings Details
5/8/2009Q1 2009($0.15)($0.18)ViewN/AView Earnings Details
3/13/2009Q4 2008($0.13)($0.21)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.14)($0.14)ViewN/AView Earnings Details
8/8/2008Q2 2008($0.13)($0.14)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.12)($0.13)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.09)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Halozyme Therapeutics (NASDAQ:HALO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Halozyme Therapeutics (NASDAQ HALO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 85.68%
Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)
Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ HALO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00233,176View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00155,000View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00280,000View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Halozyme Therapeutics (NASDAQ HALO) News Headlines

Source:
DateHeadline
Halozyme (HALO) Downgraded by BidaskClubHalozyme (HALO) Downgraded by BidaskClub
www.americanbankingnews.com - May 18 at 3:09 PM
Halozyme, Inc. (HALO) Expected to Announce Quarterly Sales of $30.90 MillionHalozyme, Inc. (HALO) Expected to Announce Quarterly Sales of $30.90 Million
www.americanbankingnews.com - May 18 at 4:24 AM
Halozyme (HALO) Downgraded by ValuEngine to "Hold"Halozyme (HALO) Downgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 17 at 10:54 PM
TheStreet Lowers Halozyme (HALO) to CTheStreet Lowers Halozyme (HALO) to C
www.americanbankingnews.com - May 17 at 3:27 PM
 Brokerages Anticipate Halozyme, Inc. (HALO) to Announce -$0.23 Earnings Per Share Brokerages Anticipate Halozyme, Inc. (HALO) to Announce -$0.23 Earnings Per Share
www.americanbankingnews.com - May 16 at 12:42 PM
Todays Research Reports on Trending Tickers: OPKO Health and Halozyme TherapeuticsToday's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics
finance.yahoo.com - May 15 at 8:50 AM
Halozyme (HALO) Cut to Underweight at BarclaysHalozyme (HALO) Cut to Underweight at Barclays
www.americanbankingnews.com - May 11 at 6:33 PM
Halozyme (HALO) Posts  Earnings Results, Beats Estimates By $0.03 EPSHalozyme (HALO) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - May 11 at 2:50 PM
Halozyme Therapeutics (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call TranscriptHalozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 8:56 AM
Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 8:56 AM
BRIEF-Halozyme Reports Q1 Loss Per Share $0.19BRIEF-Halozyme Reports Q1 Loss Per Share $0.19
www.reuters.com - May 10 at 5:37 PM
Halozyme Reports First Quarter 2018 ResultsHalozyme Reports First Quarter 2018 Results
finance.yahoo.com - May 10 at 5:37 PM
Halozyme Therapeutics: 1Q Earnings SnapshotHalozyme Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:37 PM
Halozyme (HALO) Upgraded to Buy by ValuEngineHalozyme (HALO) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - May 3 at 4:24 PM
Form 4 HALOZYME THERAPEUTICS For: May 02 Filed by: Henderson Jeffrey WilliamForm 4 HALOZYME THERAPEUTICS For: May 02 Filed by: Henderson Jeffrey William
www.streetinsider.com - May 3 at 8:31 AM
Halozyme Sees Unusually Large Options Volume (HALO)Halozyme Sees Unusually Large Options Volume (HALO)
www.americanbankingnews.com - May 1 at 7:16 AM
Halozyme (HALO) to Release Earnings on MondayHalozyme (HALO) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 5:22 AM
Halozyme, Inc. (HALO) Expected to Post Quarterly Sales of $29.21 MillionHalozyme, Inc. (HALO) Expected to Post Quarterly Sales of $29.21 Million
www.americanbankingnews.com - April 30 at 2:10 AM
Halozyme, Inc. (HALO) Receives Average Rating of "Hold" from AnalystsHalozyme, Inc. (HALO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 29 at 5:57 PM
Halozyme, Inc. (HALO) Expected to Announce Earnings of -$0.21 Per ShareHalozyme, Inc. (HALO) Expected to Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 28 at 9:14 PM
MabVax Therapeutics (MBVX) Announces Results of Antibody Program in Three Poster Presentations at 2018 AACR MeetingsMabVax Therapeutics (MBVX) Announces Results of Antibody Program in Three Poster Presentations at 2018 AACR Meetings
www.streetinsider.com - April 19 at 8:33 AM
Canaccord Genuity Analysts Give Halozyme Therapeutics (HALO) a $16.00 Price TargetCanaccord Genuity Analysts Give Halozyme Therapeutics (HALO) a $16.00 Price Target
www.americanbankingnews.com - April 15 at 8:22 PM
Zacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) Will Post Quarterly Sales of $29.54 MillionZacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) Will Post Quarterly Sales of $29.54 Million
www.americanbankingnews.com - April 13 at 1:58 AM
Halozyme Therapeutics, Inc. (HALO) Expected to Post Earnings of -$0.21 Per ShareHalozyme Therapeutics, Inc. (HALO) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - April 11 at 9:16 PM
Piper Jaffray Analysts Give Halozyme Therapeutics (HALO) a $20.00 Price TargetPiper Jaffray Analysts Give Halozyme Therapeutics (HALO) a $20.00 Price Target
www.americanbankingnews.com - April 10 at 10:31 PM
Abzena Notes Termination Of Agreement With Halozyme TherapeuticsAbzena Notes Termination Of Agreement With Halozyme Therapeutics
www.lse.co.uk - April 10 at 8:49 AM
Halozyme To Host First Quarter 2018 Financial Results Conference CallHalozyme To Host First Quarter 2018 Financial Results Conference Call
finance.yahoo.com - April 10 at 8:49 AM
BRIEF-Abzena Gets Notice From Halozyme Of Termination Of AgreementBRIEF-Abzena Gets Notice From Halozyme Of Termination Of Agreement
www.reuters.com - April 9 at 8:44 AM
Form DEFA14A HALOZYME THERAPEUTICSForm DEFA14A HALOZYME THERAPEUTICS
www.streetinsider.com - April 6 at 5:26 PM
Halozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by BrokeragesHalozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 5:38 PM
Halozyme Therapeutics (HALO) PT Raised to $18.00Halozyme Therapeutics (HALO) PT Raised to $18.00
www.americanbankingnews.com - April 1 at 9:46 AM
Halozyme Therapeutics (HALO) Cut to "Hold" at BidaskClubHalozyme Therapeutics (HALO) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 2:18 PM
$29.54 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter$29.54 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - March 27 at 1:56 AM
Halozyme Therapeutics (HALO) Upgraded to Buy by Zacks Investment ResearchHalozyme Therapeutics (HALO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 26 at 5:58 PM
Zacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) to Announce -$0.21 Earnings Per ShareZacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) to Announce -$0.21 Earnings Per Share
www.americanbankingnews.com - March 25 at 11:14 PM
Halozyme Therapeutics (HALO) and Eisai (ESALY) Head-To-Head SurveyHalozyme Therapeutics (HALO) and Eisai (ESALY) Head-To-Head Survey
www.americanbankingnews.com - March 24 at 7:14 AM
Halozyme Therapeutics (HALO) Upgraded by TheStreet to "B-"Halozyme Therapeutics (HALO) Upgraded by TheStreet to "B-"
www.americanbankingnews.com - March 24 at 12:28 AM
Halozyme Therapeutics (HALO) Raised to Strong-Buy at BidaskClubHalozyme Therapeutics (HALO) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 23 at 7:56 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc.
finance.yahoo.com - March 23 at 8:40 AM
Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder MeetingHalozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting
finance.yahoo.com - March 22 at 5:23 PM
Halozyme Therapeutics (HALO) to Present Data From Six ... - StreetInsider.comHalozyme Therapeutics (HALO) to Present Data From Six ... - StreetInsider.com
www.streetinsider.com - March 16 at 8:38 AM
Halozyme Therapeutics (HALO) to Present Data From Six Nonclinical Studies at AACRHalozyme Therapeutics (HALO) to Present Data From Six Nonclinical Studies at AACR
www.streetinsider.com - March 15 at 8:34 AM
Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual ConferenceHalozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
finance.yahoo.com - March 14 at 6:46 PM
Global Antidiabetics Market Opportunities 2018: Eli Lilly, Boehringer Ingelheim, Novo NordiskGlobal Antidiabetics Market Opportunities 2018: Eli Lilly, Boehringer Ingelheim, Novo Nordisk
www.marketwatch.com - March 14 at 9:00 AM
QCOM Jeffrey William Henderson Insider Trades for Qualcomm Inc.QCOM Jeffrey William Henderson Insider Trades for Qualcomm Inc.
www.marketwatch.com - March 13 at 7:05 PM
Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from BrokeragesHalozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 10 at 5:41 PM
 Analysts Anticipate Halozyme Therapeutics, Inc. (HALO) to Post -$0.20 Earnings Per Share Analysts Anticipate Halozyme Therapeutics, Inc. (HALO) to Post -$0.20 Earnings Per Share
www.americanbankingnews.com - March 8 at 4:15 PM
Senzar Asset Management LLC Has $10.89 Million Position in Halozyme Therapeutics, Inc. (HALO)Senzar Asset Management LLC Has $10.89 Million Position in Halozyme Therapeutics, Inc. (HALO)
www.americanbankingnews.com - March 5 at 3:44 PM
Halozyme Therapeutics, Inc. (HALO) Shares Sold by Kennedy Capital Management Inc.Halozyme Therapeutics, Inc. (HALO) Shares Sold by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 5 at 11:39 AM
97,707 Shares in Halozyme Therapeutics, Inc. (HALO) Purchased by Schroder Investment Management Group97,707 Shares in Halozyme Therapeutics, Inc. (HALO) Purchased by Schroder Investment Management Group
www.americanbankingnews.com - March 5 at 9:40 AM

SEC Filings

Halozyme Therapeutics (NASDAQ:HALO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Halozyme Therapeutics (NASDAQ:HALO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Halozyme Therapeutics (NASDAQ HALO) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.